Skip to main content
Intellia Therapeutics Inc (NTLA)
Drugs • Health Care
Stock AI
News & Reports
July 30, 2026 Intellia Therapeutics to Discuss Second Quarter 2026 Financial Results in Upcoming Conference Call Intellia Therapeutics Inc. will hold a conference call on August 6, 2026, to discuss its Q2 financial results and provide updates on its gene-editing therapies. Investors will be keen to hear about revenue, cash flow, and advancements in clinical trials amid a rapidly evolving biotech landscape.
July 06, 2026 Intellia Therapeutics Expands Workforce with Inducement Grants Intellia Therapeutics announced the awarding of inducement grants to thirteen new employees as part of its 2024 Inducement Plan. These grants, comprising time-based RSUs, aim to attract top talent in the biotech sector and promote long-term commitment, vital for the company's mission of transforming medicine through innovative treatments.
June 13, 2026 Intellia Therapeutics Reports Positive Phase 3 Results for Lonvoguran Ziclumeran in Hereditary Angioedema Intellia Therapeutics announced positive Phase 3 results for lonvoguran ziclumeran (lonvo-z) in treating hereditary angioedema, showing an 87% reduction in monthly attacks. The drug, based on CRISPR technology, has potential for regulatory approval in 2027, offering hope for patients suffering from this rare genetic condition.
June 05, 2026 Intellia Therapeutics Announces Inducement Grants to New Employees Intellia Therapeutics has announced inducement grants of 47,150 RSUs to six new employees as part of its 2024 Inducement Plan. This strategic initiative aims to attract and retain top talent in the competitive biopharmaceutical industry, aligning employee interests with shareholders.
June 01, 2026 Intellia Therapeutics to Present Groundbreaking Phase 3 Data on Lonvoguran Ziclumeran at EAACI 2026 Intellia Therapeutics will present Phase 3 data for Lonvoguran Ziclumeran at EAACI 2026, showcasing its potential to transform hereditary angioedema treatment. The presentation will highlight efficacy, safety, and patient experiences, emphasizing a revolutionary approach to this rare genetic disorder.
May 11, 2026 Intellia Therapeutics Reports First Quarter 2026 Financial Results and Significant Business Developments Intellia Therapeutics reports a strong start to 2026 with positive Phase 3 data for lonvo-z, aimed at treating Hereditary Angioedema. The company also resumes trials for nex-z in ATTR amyloidosis and strengthens its financial position with a public offering.
May 11, 2026 Intellia Therapeutics Inc. Reports Q1 2026 Financial Performance: Progress Amidst Challenges Intellia Therapeutics reports its Q1 2026 financial results, showcasing advancements in clinical trials for lonvo-z and nex-z while managing operational expenses. The company aims for profitability through strategic initiatives and potential product launches in the coming years.
May 05, 2026 Intellia Therapeutics Announces Participation in Key Investor Conferences Intellia Therapeutics will engage investors through key fireside chats at prominent healthcare conferences in May and June 2026. These sessions will provide insights into the company's CRISPR gene editing advancements and strategic directions. Live webcasts will be available for interested audiences.
May 01, 2026 Intellia Therapeutics Announces Inducement Grants to New Employees On May 1, 2026, Intellia Therapeutics granted inducement awards to 43 new employees, totaling 208,850 shares to enhance recruitment efforts. This strategic move aligns with Nasdaq regulations and reflects the company's commitment to innovation in biotechnology.
April 29, 2026 Intellia Therapeutics Announces Public Offering of Common Stock Intellia Therapeutics has announced a public offering of common stock to raise approximately $180 million for its CRISPR gene editing initiatives. The offering involves 16.7 million shares priced at $10.75 each, with underwriters having an option for additional shares. This move is crucial for funding ongoing research and development in biopharmaceuticals.
April 27, 2026 Intellia Therapeutics Inc. Proposes $150 Million Public Offering Intellia Therapeutics has announced a $150 million public offering as it advances its mission to develop innovative CRISPR-based treatments. Managed by Jefferies, Goldman Sachs, and Citigroup, the offering reflects the company's commitment to revolutionizing medicine despite market uncertainties.
April 27, 2026 Intellia Therapeutics Reports Groundbreaking Phase 3 Results for Lonvo-z in Hereditary Angioedema Intellia Therapeutics reported impressive results from the Phase 3 HAELO trial for lonvo-z, demonstrating an 87% reduction in HAE attacks. The positive outcomes pave the way for a potential FDA approval and market launch in 2027.
April 27, 2026 Intellia Therapeutics Makes Strides in Gene Editing with FDA Submission for Lonvoguran Ziclumeran Intellia Therapeutics has initiated a rolling BLA submission for lonvoguran ziclumeran, a one-time gene editing therapy for hereditary angioedema. Positive Phase 3 trial results suggest it could revolutionize treatment by offering a permanent solution. The FDA's RMAT designation accelerates the review process, with a potential launch in early 2027.
April 24, 2026 Intellia Therapeutics Set to Unveil Pivotal Data on Lonvoguran Ziclumeran for Hereditary Angioedema Intellia Therapeutics will unveil crucial data from its Phase 3 trial of lonvoguran ziclumeran for hereditary angioedema on April 27, 2026. This therapy could significantly change treatment options for a condition that severely impacts patients' lives.
April 03, 2026 Intellia Therapeutics Induces New Talent with Strategic Stock Grants Intellia Therapeutics has awarded inducement grants of 67,150 shares to 13 new employees to attract top talent and enhance its workforce. This strategic move aligns employees' interests with shareholders, supporting the company's growth in the competitive biopharmaceutical sector.
March 06, 2026 Intellia Therapeutics Announces Inducement Grants in Compliance with Nasdaq Regulations Intellia Therapeutics has issued inducement grants to six new employees, comprising 16,500 RSUs, to bolster its recruitment strategy and align employee interests with company goals. This move reflects Intellia's commitment to innovation in CRISPR gene editing and its dedication to driving growth in the biotechnology sector.
March 03, 2026 Intellia Therapeutics Unveils Promising Lonvoguran Ziclumeran Data at AAAAI 2026 Intellia Therapeutics presented promising data on Lonvoguran Ziclumeran at AAAAI 2026, demonstrating long-term efficacy and safety for Hereditary Angioedema treatment. With a significant reduction in attack rates and a focus on patient-centered care, Lonvo-z could revolutionize HAE management.
March 02, 2026 Intellia Therapeutics Lifts Clinical Hold on MAGNITUDE Phase 3 Trial, Paving the Way for Nexiguran Ziclumeran in ATTR-CM Intellia Therapeutics has resumed its MAGNITUDE Phase 3 trial for nexiguran ziclumeran after the FDA lifted a clinical hold. The trial aims to evaluate the drug's efficacy and safety in treating ATTR-CM, implementing enhanced safety measures to protect patients. This marks a significant step forward in developing CRISPR-based therapies for amyloidosis.
February 26, 2026 Intellia Therapeutics Reports Encouraging Financial Results and Clinical Progress in Q4 2025 Intellia Therapeutics reported positive financial results and clinical progress in Q4 2025, showcasing promising data for its therapies Lonvo-z and Nex-z. The company is focused on advancing these groundbreaking treatments while navigating regulatory challenges and maintaining financial health.
February 26, 2026 Intellia Therapeutics Inc. Reports 2025 Annual Results: Progress Amidst Financial Challenges Intellia Therapeutics' 2025 annual report showcases a revenue increase to $67.7 million, despite a net loss of $412.6 million. The company emphasizes its commitment to R&D and strategic collaborations to sustain growth in the competitive biopharmaceutical field.
February 24, 2026 Intellia Therapeutics Announces Participation in Key Investor Conferences Intellia Therapeutics will participate in major investor conferences in March 2026, emphasizing their commitment to gene editing advancements. Live webcasts will provide insights into their innovative CRISPR-based therapies.
February 19, 2026 Intellia Therapeutics Set to Reveal 2025 Financial Results and Strategic Updates Intellia Therapeutics will host a conference call on February 26, 2026, to discuss its 2025 financial results and strategic updates. Investors can participate via webcast or telephone to gain insights into the company's advancements in CRISPR-based therapies and future direction.
February 06, 2026 Intellia Therapeutics Expands Workforce with Inducement Grants Intellia Therapeutics has issued inducement grants to six new employees as part of its strategy to attract talent in the competitive biotech sector. These grants, comprising restricted stock units, aim to enhance the company's research and development capabilities in gene editing.
January 27, 2026 Intellia Therapeutics Lifts Clinical Hold on MAGNITUDE-2 Trial: A Landmark Step in Gene Editing Intellia Therapeutics has lifted the clinical hold on its MAGNITUDE-2 trial for nexiguran ziclumeran, a promising gene therapy for hereditary transthyretin amyloidosis. The FDA's approval allows patient enrollment to resume, with enhanced safety measures in place. This trial represents a significant step in developing innovative treatments for genetic disorders.
January 07, 2026 Intellia Therapeutics to Showcase Innovations at J.P. Morgan Healthcare Conference Intellia Therapeutics is set to present at the J.P. Morgan Healthcare Conference, highlighting their CRISPR advancements and future strategies. Their commitment to gene editing could revolutionize treatments and attract significant investor interest.
January 02, 2026 Intellia Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics has announced inducement grants of 22,800 RSUs to new employees under its 2024 Inducement Plan, emphasizing its commitment to talent acquisition. These grants align with Nasdaq rules and support the company's mission of advancing CRISPR-based therapies.
December 05, 2025 Intellia Therapeutics Announces Inducement Grants to New Employees Intellia Therapeutics has issued inducement grants under its 2024 plan to attract new employees, awarding 12,600 RSUs vesting over three years. This strategic move aims to enhance its competitive edge in gene editing and maintain talent retention.
November 10, 2025 Intellia Therapeutics Reports Promising Phase 1 Results for Nexiguran Ziclumeran in ATTR Amyloidosis Intellia Therapeutics announced promising Phase 1 trial results for nexiguran ziclumeran, showing significant reductions in transthyretin levels and stabilization in patients with advanced ATTR amyloidosis. The treatment demonstrated a favorable safety profile and potential for impactful clinical benefits, despite regulatory challenges ahead.
November 08, 2025 Intellia Therapeutics Reports Promising Data from Lonvoguran Ziclumeran in Hereditary Angioedema Intellia Therapeutics reported impressive results from its Phase 1/2 trial of lonvoguran ziclumeran, with 97% of patients remaining attack-free. The treatment shows potential for redefining hereditary angioedema management with a favorable safety profile and significant efficacy.
November 06, 2025 Intellia Therapeutics Reports Q3 2025 Results Amid Clinical Challenges Intellia Therapeutics reported its Q3 2025 results, highlighting challenges with its lead product nex-z due to a clinical hold after adverse events. Despite this, progress continues with lonvo-z, which is set for a BLA submission in 2026. The company is navigating these hurdles while managing its financial outlook.
November 06, 2025 Intellia Therapeutics Inc.: 2025 Q3 Financial Overview and Pipeline Developments Intellia Therapeutics has reported a revenue increase in Q3 2025, driven by collaboration agreements, despite a net loss. The company faces regulatory challenges while advancing its gene-editing pipeline, particularly in hereditary angioedema and transthyretin amyloidosis.
October 27, 2025 Intellia Therapeutics Pauses Clinical Trials for Nexiguran Ziclumeran Amid Safety Concerns Intellia Therapeutics has paused its MAGNITUDE clinical trials for nexiguran ziclumeran following a serious adverse event in a patient. The company prioritizes patient safety while investigating the incident and consulting with regulatory authorities. The outcome could significantly impact the future of gene-editing therapies.
October 03, 2025 Intellia Therapeutics Expands Talent Pool with Inducement Grants Intellia Therapeutics announced the issuance of inducement grants to attract top talent in gene editing. This strategic move aims to strengthen its research efforts and enhance its competitive edge in biotechnology.
September 25, 2025 Intellia Therapeutics Reports Encouraging Long-Term Results for Nexiguran Ziclumeran in ATTR Amyloidosis Intellia Therapeutics announced encouraging long-term data from its Phase 1 study of Nexiguran Ziclumeran, showing significant serum TTR reductions in ATTR amyloidosis patients. The treatment demonstrated a favorable safety profile and is advancing into Phase 3 trials, potentially transforming outcomes for this rare disease.
September 22, 2025 Intellia Therapeutics Unveils Promising Data for Nexiguran Ziclumeran in ATTR Amyloidosis Treatment Intellia Therapeutics is set to present significant data on Nexiguran Ziclumeran, a promising CRISPR-based treatment for hereditary ATTR amyloidosis, at an upcoming international conference. The findings from a Phase 1 trial indicate lasting reductions in TTR levels, which could transform patient care for this rare disease.
August 07, 2025 Intellia Therapeutics Reports Promising Developments Amid Q2 2025 Financial Results Intellia Therapeutics has reported its Q2 2025 financial results, showing a reduced net loss of $101.2 million and promising advancements in CRISPR-based therapies. With a strong cash position of $630.5 million and strategic collaborations, the company is poised for future growth despite current financial challenges.
May 08, 2025 Intellia Therapeutics Inc. Reports 2025 Q1 Financial Results: A Mixed Bag Amid Promising Developments Intellia Therapeutics reported a net income loss of $114.3 million in Q1 2025, reflecting ongoing investments in its pipeline. Despite financial challenges, the company is making strides with lead therapies targeting genetic diseases, such as NTLA-2002 and nex-z, and maintains a strong cash position for future growth.
April 14, 2025 Legal Challenges Loom for Intellia Therapeutics as Class Action Lawsuit Emerges Intellia Therapeutics is facing a class action lawsuit from the Schall Law Firm for allegedly misleading investors about its drug NTLA-3001. The lawsuit highlights claims of false statements made during a critical period, leading to significant financial losses for shareholders. Investors are urged to take action before the April 14, 2025 deadline.
April 14, 2025 Intellia Therapeutics Faces Legal Scrutiny Amid Strategic Shift Intellia Therapeutics is embroiled in a federal securities class action lawsuit alleging misleading statements about its drug pipeline. Following a strategic restructuring and significant stock price decline, the company is urging investors to act before the April 14, 2025 deadline.
April 11, 2025 Intellia Therapeutics Faces Class Action Lawsuit Amid Allegations of Misleading Investors Intellia Therapeutics is facing a class action lawsuit filed by the Rosen Law Firm on behalf of investors who claim the company misled them about its clinical trials. Allegations focus on undisclosed information regarding a decline in demand for their gene editing technologies. Affected shareholders have options to join the lawsuit and seek compensation.
March 26, 2025 Intellia Therapeutics Receives FDA RMAT Designation for Nexiguran Ziclumeran in Amyloidosis Treatment Intellia Therapeutics has achieved FDA RMAT designation for its investigational therapy, nexiguran ziclumeran, targeting transthyretin amyloidosis. This designation accelerates development and emphasizes the therapy's promise in treating this rare condition. With CRISPR technology at its core, nex-z could transform treatment approaches for patients suffering from ATTR.
March 04, 2025 SWOT Analysis of Intellia Therapeutics Inc in 2025 This article provides a comprehensive SWOT analysis of Intellia Therapeutics Inc in 2025, detailing its strengths in CRISPR technology, weaknesses like a lack of revenue, and opportunities in gene therapy markets, alongside potential threats from competition and regulation.
March 04, 2025 Intellia Therapeutics Expands Workforce with Strategic Inducement Grants Intellia Therapeutics has introduced strategic inducement grants to attract eleven new hires, offering 32,600 restricted stock units to enhance its workforce. This initiative underscores the company's commitment to innovation in gene editing and aligns employee interests with long-term goals.
February 27, 2025 Intellia Therapeutics Inc. 2024 Annual Report: A Year of Challenges and Progress Intellia Therapeutics' 2024 annual report highlights significant revenue growth to $57.9 million despite increased expenses and ongoing legal challenges. The company continues to advance its gene editing therapies and strategic collaborations, positioning itself for future growth in the biotechnology sector.
February 27, 2025 Intellia Therapeutics Reports Strong Fourth Quarter and Full-Year 2024 Results Intellia Therapeutics reported strong Q4 and full-year 2024 results, showcasing progress in CRISPR-based therapies for hereditary angioedema and ATTR amyloidosis. The company emphasizes its strategic focus on late-stage programs and plans upcoming regulatory submissions.
February 25, 2025 Intellia Therapeutics Faces Class Action Lawsuit Amid Investor Concerns Intellia Therapeutics is facing a class action lawsuit for allegedly misleading investors about NTLA-3001's development and potential. The lawsuit highlights misrepresentations, overly optimistic timelines, and sustainability issues, urging affected investors to join. This case could impact the company's reputation and the broader biopharmaceutical sector.
February 20, 2025 Intellia Therapeutics Announces Upcoming Conference Call for Q4 and Full-Year 2024 Results Intellia Therapeutics has scheduled a conference call for February 27, 2025, to discuss its Q4 and full-year 2024 results. Investors can join via phone or webcast, with a replay available afterward. The event promises insights into the company's advancements in CRISPR-based therapies.
February 12, 2025 Intellia Therapeutics Faces Class Action Lawsuit Amid Allegations of Securities Fraud Intellia Therapeutics is facing a class action lawsuit over allegations of securities fraud related to its drug NTLA-3001. The lawsuit claims the company misled investors about its drug development capabilities, leading to significant financial losses. Investors are urged to act before the April 14, 2025 deadline.
November 07, 2024 Intellia Therapeutics Inc. Reports Mixed Results for Q3 2024 Intellia Therapeutics Inc. reported a net loss of $135.7 million in Q3 2024, a rise from the previous year. Despite financial challenges, the company continues to advance its clinical programs and form strategic partnerships, signaling potential for future growth.
August 08, 2024 Intellia Therapeutics Inc. Reports Q2 2024 Financial Results: A Deep Dive into Performance and Future Outlook Intellia Therapeutics Inc. reports a net loss of $146.9 million in Q2 2024, alongside declining revenues and increased R&D expenses. The company emphasizes collaboration success while outlining future funding strategies to support its clinical pipeline.
May 09, 2024 Intellia Therapeutics Inc. Reports Q1 2024 Results: A Step Forward in Gene Editing Intellia Therapeutics reported its Q1 2024 financial results, showcasing a significant increase in collaboration revenue and ongoing advancements in its gene editing pipeline. Despite a net loss, the company remains optimistic about future growth through strategic partnerships and innovative therapies.

Intellia Therapeutics Announces Participation in Key Investor Conferences

Last updated: February 24, 2026 •
Taurigo

1. Company to Showcase Innovations in Gene Editing

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a prominent player in the field of gene editing, has officially announced its participation in several important investor conferences scheduled for early March 2026. This announcement signals the company’s commitment to transparency and engagement with investors as it continues to pave the way in CRISPR-based therapies.

2. Upcoming Conferences

The details of the conferences are as follows:

TD Cowen 46th Annual Health Care Conference

  • Date: Tuesday, March 3, 2026
  • Fireside Chat Time: 1:10 p.m. ET
  • Location: Boston, MA

Leerink Global Healthcare Conference

  • Date: Monday, March 9, 2026
  • Fireside Chat Time: 8:40 a.m. ET
  • Location: Miami, FL

Barclays 28th Annual Global Healthcare Conference

  • Date: Tuesday, March 10, 2026
  • Location: Miami, FL

3. Live Webcasts and Replays

Intellia has announced that the fireside chats for the TD Cowen and Leerink conferences will be webcast live, allowing a broader audience to engage with the discussions surrounding their innovative approaches in gene therapy. Interested parties can access the webcasts by visiting the Events and Presentations page in the Investors & Media section on the company's website at intelliatx.com. Additionally, replays of these webcasts will be available for approximately 90 days following the events, ensuring that stakeholders and interested investors can stay informed about the latest developments in Intellia's research and operations.

4. About Intellia Therapeutics

Intellia Therapeutics is recognized for its pioneering work in the gene editing landscape, specifically utilizing CRISPR technology to develop groundbreaking therapies aimed at addressing significant unmet medical needs. The company’s mission is not only to create first-in-class medicines but also to reshape the treatment paradigms for various patient populations. With a robust foundation of scientific and technical expertise, Intellia is continually enhancing its CRISPR-based platform through novel editing and delivery technologies.

5. Conclusion

The participation of Intellia Therapeutics in these key investor conferences reflects the company’s proactive approach to investor relations and its ongoing ambition to lead in the field of gene editing. As the healthcare landscape evolves, events such as these provide a crucial platform for companies like Intellia to connect with investors, share their vision, and highlight their advancements in revolutionary therapies. Investors and industry stakeholders will be eagerly watching to see how Intellia continues to innovate and influence the future of medicine.

Original press release
You may also be interested in:
Products
Resources
Legal
Company
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.